Publication | Open Access

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

UrologyOncologyGenitourinary CancerMedicinePhase Ii StudyImmune Checkpoint InhibitorUrothelial Cancer PatientsCancer TreatmentPharmacologyTumor Contrast EnhancementTumor Microenvironment